BPG致力于知识的发现和传播
本文章
![](https://www.f6publishing.com/contents/images/collapsed_yes.gif)
本文章的学术内容和语言评估
![](https://www.f6publishing.com/contents/images/collapsed_yes.gif)
本文章的CrossCheck查重和Google搜索
![](https://www.f6publishing.com/contents/images/collapsed_yes.gif)
本文章的引用
Yang XY, Yu YF, Tong KK, Hu G, Yu R, Su LJ. Efficacy and safety of Xileisan combined with mesalazine for ulcerative colitis: A meta-analysis and trial sequential analysis. World J Clin Cases 2024; 12(21): 4703-4716 [DOI: 10.12998/wjcc.v12.i21.4703]
![](https://www.f6publishing.com/contents/images/collapsed_yes.gif)
本文章的通讯作者
Lian-Jun Su, Doctor, School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, No. 300 Xueshi Road, Hanpu Science and Education Park, Yuelu District, Changsha 410208, Hunan Province, China. sulianjun@hnucm.edu.cn
![](https://www.f6publishing.com/contents/images/collapsed_yes.gif)
本文章的研究领域
Gastroenterology & Hepatology
![](https://www.f6publishing.com/contents/images/collapsed_yes.gif)
本文章的类型
Meta-Analysis
![](https://www.f6publishing.com/contents/images/collapsed_yes.gif)
本文章的开放获取政策
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
![](https://www.f6publishing.com/contents/images/collapsed_yes.gif)
本文章的Google引用次数
本文章的点击和下载次数
- 本文章浏览次数 (0)
All Articles published online
|
Jul 26, 2024 (publication date) through Jun 30, 2024
本文章的被引频次
- 被引频次 (0)
本文章的期刊信息
出版物名称
World Journal of Clinical Cases
ISSN
2307-8960
本文章的出版商
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Total Visits of This Article
2020 | 总访问次数
排名 | 国家/地区 | 数量 | 占比 |